The most troublesome symptoms in most patients with acquired neuropathy are...
Our laboratory seeks to understand the molecular mechanisms that lead to axon degeneration and the diseases that stem from this degenerative process. We focus our studies on axon/glial interactions and the responses of neurons and glia to axon injury and disease. In particular, we aim to define, in studies performed collaboratively with Aaron DiAntonio’s lab, the molecular program responsible for dismantling injured and/or unhealthy axons. We also study the mechanisms by which disruption of glial cell metabolism leads to axon dysfunction and degeneration. Our laboratory utilizes cutting-edge technologies including Cas9-mediated genome engineering, metabolomics, and high-content screening to manipulate and analyze axon/glial interactions in health and disease. In our research, we utilize mutant mice, primary neuronal and Schwann cell cultures, and iPSC-derived neurons. Our overriding goal is to help develop new treatments for patients with neurodegenerative conditions through fundamental mechanistic research.
Kow Essuman was admitted to the Medical Science Training Program (MSTP), a combined MD/PhD program at Washington University in St. Louis. Kow began his studies in the MD program at Washington University in 2012, and gained admission to the MSTP program in February 2017. He is currently defining molecular pathways that underlie the axon self-destruction program in neurons. He hopes his findings...